TY - PAT
T1 - Compositions And Methods For Altering Immune Function
AU - Miller, Stephen
N1 - filingdate: 2006-6-1
issueddate: 2009-10-13
Status: published
attorneydocketnumber: 2005-008-03
PY - 2009/10/13
Y1 - 2009/10/13
N2 - Targeted Enhancement of CD154 Trimer Stability for Modulation of Immune Function
NU 2005-008
Inventors
Laurence Howard
John Irwin
Stephen Miller*
Brian Shoichet
Abstract
Regulating immune cell response is critical in combating disease. Northwestern researchers have developed a new therapy that can either inhibit immune cell function in autoimmune disease or enhance natural or vaccine-facilitated immune responses. A small molecule was identified that can modulate the immune response by stabilizing an active but transient CD154 trimer, which is central to a type 1 helper T-cell immune response and immune effector function. The compound performed successfully in a mouse model, demonstrating its ability to enhance an immune response in a living animal. Results in a mouse cancer model show promise with regard to both tumor reduction and decreased metastasis. The small molecule may prove useful in the treatment of a wide variety of medical conditions.
Applications
o Vaccine therapy: protect against infectious or toxic agents
o Therapeutics: autoimmune disease, cancer, infectious disease, immunotherapy
Advantages
o Demonstrated success in a mammalian system
o Applicable to multiple diseases
IP Status
Issued US Patent 7,601,355
Marketing Contact
Michael Moore, PhD
Invention Manager
(p) (847) 491-4645
(e) michaelmoore@northwestern.edu
AB - Targeted Enhancement of CD154 Trimer Stability for Modulation of Immune Function
NU 2005-008
Inventors
Laurence Howard
John Irwin
Stephen Miller*
Brian Shoichet
Abstract
Regulating immune cell response is critical in combating disease. Northwestern researchers have developed a new therapy that can either inhibit immune cell function in autoimmune disease or enhance natural or vaccine-facilitated immune responses. A small molecule was identified that can modulate the immune response by stabilizing an active but transient CD154 trimer, which is central to a type 1 helper T-cell immune response and immune effector function. The compound performed successfully in a mouse model, demonstrating its ability to enhance an immune response in a living animal. Results in a mouse cancer model show promise with regard to both tumor reduction and decreased metastasis. The small molecule may prove useful in the treatment of a wide variety of medical conditions.
Applications
o Vaccine therapy: protect against infectious or toxic agents
o Therapeutics: autoimmune disease, cancer, infectious disease, immunotherapy
Advantages
o Demonstrated success in a mammalian system
o Applicable to multiple diseases
IP Status
Issued US Patent 7,601,355
Marketing Contact
Michael Moore, PhD
Invention Manager
(p) (847) 491-4645
(e) michaelmoore@northwestern.edu
M3 - Patent
M1 - 7601355
ER -